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Abstract
Background: With the advent of anti-Helicobacter pylori therapy, hospital admissions for peptic ulcer disease
(PUD) have declined significantly since the 1990s. Despite this, operative treatment of PUD still is common.
Although previous papers suggest that Candida in peritoneal fluid cultures may be associated with worse out-
comes in patients with perforated peptic ulcers (PPUs), post-operative anti-fungal therapy has not been effective.
We hypothesized that pre-operative anti-fungal drugs improve outcomes in patients with PPUs undergoing
operative management.
Patients and Methods: A prospectively maintained Acute and Critical Care Surgery (ACCS) database spanning
2008–2015 and including more than 7,000 patients was queried for patients with PPUs. Demographics and
clinical outcomes were abstracted. Pre-operative anti-fungal use, intra-operative peritoneal fluid cultures, and
infectious outcomes were abstracted manually. We compared outcomes and the presence of fungal infections in
patients receiving peri-operative anti-fungal drugs in the entire cohort and in patients with intra-operative
peritoneal fluid cultures. Frequencies were compared by the Fisher exact or w2 test as appropriate. The
Student’s t-test was used for continuous variables.
Results: There were 107 patients with PPUs who received operative management; 27 (25.2%) received pre-
operative anti-fungal therapy; 33 (30.8%) received peritoneal fluid culture, and 17 cultures (51.5%) were
positive for fungus. The presence of fungus in the cultures did not affect the outcomes. There were no
differences in length of stay (LOS), intensive care unit (ICU) LOS, ventilator days, 30-day re-admission rates,
or rates of intra-abdominal abscess formation or fungemia in patients who received pre-operative anti-fungal
drugs regardless of the presence of fungi in the peritoneal fluid.
Conclusion: Candida has been recovered in 29%–57% of peritoneal fluid cultures in patients with PPUs.
However, no studies have evaluated pre-operative anti-fungal therapy in PPUs. Our data suggest that pre-
operative anti-fungal drugs are unnecessary in patients undergoing operative management for PPU.
Keywords: candida; fungus; gastrointestinal perforation; peritonitis
In 1994, the National Institutes of Health released aconsensus statement attributing many cases of peptic ulcer
disease (PUD) to Helicobacter pylori and recommending
treatment for all patients with H. pylori [1]. Coupled with the
widespread availability of proton pump inhibitors (PPIs) and
histamine-2 receptor antagonists (H2 blockers), there have
been significant decreases in hospitalizations for complica-
tions of PUD in the past 20 years. Wang et al. noted an almost
30% decrease in admission from complications of PUD from
1993 to 2006 [2]. During this period, perforations also de-
creased, although there were still 14,504 hospitalizations for
perforated peptic ulcers (PPUs) in 2006, which were re-
sponsible for 37% of all ulcer-related deaths in the United
States [2]. Despite the decrease in hospitalizations, operative
treatment of PUD remains one of the most common proce-
dures performed in emergency general surgery and is asso-
ciated with a complication rate of approximately 40% [3].
Perforations remain the most common emergency surgical
indication in PUD [2,4,5].
Historically, Candida has been reported in 29%–57% of
peritoneal fluid cultures in patients with PPUs [6–9]. The
impact of positive peritoneal fluid cultures is unclear. In one
series, mixed fungal and bacterial cultures were associated
with advanced age and shock. They considered the fungal
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Table 1. Demographics of Patients by Pre-Operative Anti-Fungal Therapy
and Intra-Operative Peritoneal Fluid Cultures
Total
(n = 107)










(n = 17) p
Age 55.92 (17.6) 56.2 (18.6) 55.2 (14.5) 0.81 59.3 (21.0) 57.7 ( 15.3) 0.80
Sex (%) 0.78 0.06
Female 57 (53.3) 42 (52.5) 15 (55.6) 6 (37.5) 12 ( 70.6)
Male 50 (46.7) 38 (47.5) 12 (44.4) 10 (62.5) 5 ( 29.4)
Race (%) 0.05 0.10
Caucasian 62 (57.9) 51 (63.8) 11 (40.7) 7 (43.8) 13 ( 76.5)
African American 40 (37.4) 26 (32.5) 14 (51.9) 8 (50.0) 4 ( 23.5)
Asian 2 ( 1.9) 2 ( 2.5) 0 1 ( 6.3) 0
Hispanic 0 0 0 0 0
Native American 0 0 0 0 0
Other 3 ( 2.8) 1 ( 1.3) 2 ( 7.4) 0 0
Unknown 0 0 0 0 0
Body Mass Index 26.7 ( 7.2) 26.2 ( 6.5) 28.2 ( 9.2) 0.22 26.9 ( 4.3) 29.6 ( 8.5) 0.24
Social (%)
Alcohol 30 (34.5) 20 (30.77) 10 (45.45) 0.21 4 (30.8) 6 ( 37.5) 1.00
Illicit drug use 16 (19.5) 9 (14.75) 7 (33.33) 0.11 3 (27.3) 4 ( 26.7) 1.00
Tobacco 52 (55.3) 39 (54.93) 13 (56.52) 0.89 7 (46.7) 7 ( 41.2) 0.75
Co-morbidities (%)
Myocardial infarction 8 ( 7.5) 8 (10.0) 0 0.20 3 (18.8) 2 ( 11.8) 0.66
Congestive heart failure 10 ( 9.3) 8 (10.0) 2 ( 7.4) 1.00 3 (18.8) 3 ( 17.6) 1.00
Peripheral vascular
disease
13 (12.1) 10 (12.5) 3 (11.1) 1.00 3 (18.8) 1 ( 5.9) 0.34
Cerebrovascular disease 7 ( 6.5) 5 ( 6.3) 2 ( 7.4) 1.00 3 (18.8) 0 0.10
Chronic pulmonary
disease
29 (27.1) 23 (28.7) 6 (22.2) 0.51 3 (18.8) 4 ( 23.5) 1.00
Connective tissue
disease
1 ( 0.9) 1 ( 1.3) 0 1.00 0 0 N/A
Peptic ulcer disease 99 (92.5) 75 (93.8) 24 (88.9) 0.41 15 (93.8) 17 (100) 0.48
Mild liver disease 9 ( 8.4) 6 ( 7.5) 3 (11.1) 0.69 1 ( 6.3) 3 ( 17.6) 0.60
Moderate or severe liver
disease
1 ( 0.9) 1 ( 1.3) 0 1.00 0 0 N/A
Diabetes mellitus 15 (14.0) 9 (11.3) 6 (22.2) 0.20 1 ( 6.3) 4 ( 23.5) 0.34
Diabetes mellitus with
end-organ damage
1 ( 0.9) 1 ( 1.3) 0 1.0 1 ( 6.3) 0 0.48
Hemiplegia 2 ( 1.9) 1 ( 1.3) 1 ( 3.7) 0.44 1 ( 6.3) 0 0.48
Renal disease 12 (11.2) 7 ( 8.8) 5 (18.5) 0.17 4 (25.0) 1 ( 5.9) 0.17
Any solid organ tumor 6 ( 5.6) 4 ( 5.0) 2 ( 7.4) 0.64 2 (12.5) 1 ( 5.9) 0.60
Metastatic solid-organ
tumor
6 ( 5.6) 5 ( 6.3) 1 ( 3.7) 1.0 1 ( 6.3) 2 ( 11.8) 1.00
Age-adjusted Charlson
Comorbidity Index
3.9 ( 2.95) 3.96 ( 3.1) 3.63 ( 2.6) 0.61 4.94 ( 3.3) 4.24 ( 3.73) 0.57
American Society
of Anesthesiologists Score
2.86 ( 0.86) 2.8 ( 0.89) 3.0 ( 0.72) 0.22 2.88 ( 0.89) 2.88 ( 0.70) 0.98
Duration of symptoms (h) 0.47 0.39
>24 60 (56.1) 21 (26.3) 10 (37.3) 2 (12.5) 5 ( 29.4)
<24 31 (29.0) 45 (56.3) 15 (55.6) 12 (75.0) 10 ( 58.8)
Unknown 16 (15.0) 14 (17.5) 2 ( 7.4) 2 (12.5) 2 ( 11.8)
Prior H2-blocker use (%) 3 ( 2.9) 0 3 (11.1) 0.02 1 ( 6.3) 0 1.0
Prior PPI use (%) 14 (14.7) 13 (17.3) 2 ( 7.4) 0.34 3 (18.8) 2 ( 14.3) 1.0
Location of perforation (%) 0.27 0.07
Stomach 34 (31.8) 27 (33.8) 7 (25.9) 4 (25.0) 10 ( 58.8)
Pyloric channel 16 (15.0) 10 (12.5) 6 (22.2) 0 1 ( 5.9)
Duodenum 53 (49.5) 41 (51.2) 12 (44.4) 11 (68.8) 6 ( 35.3)
Both stomach and
duodenum
3 ( 2.8) 2 ( 2.5) 1 ( 3.7) 0 0
Unknown 1 ( 0.9) 0 1 ( 3.7) 1 ( 6.3) 0
P values are from comparisons of patients who did and did not receive pre-operative anti-fungal therapy and of patients with positive and
















































species to be non-pathogenic in this setting and due to the
patient’s baseline illness [7]. In contrast, Shan et al. argued
that intra-operative peritoneal fluid cultures with fungal
growth were associated with longer hospital stays, more
deaths, and higher rates of surgical site infections. Positive
fungal cultures also were associated with higher Mannheim
Peritonitis Index (MPI) scores, indicating more severe ill-
ness at presentation [9,10].
Although there have been several studies examining the
impact of peri-operative anti-fungal use in patients with
gastrointestinal perforations, all of them focused on post-
operative use or included only a few patients with perforated
ulcers [11–15]. To our knowledge, there have been no studies
examining the relation between pre-operative use of anti-
fungal drugs and outcomes of patients undergoing surgery for
PPUs in the era of readily available PPIs and H2 blockers. We
hypothesized that pre-operative anti-fungal use improves
outcomes in patients with PPUs.
Patients and Methods
An Institutional Review Board-approved, prospectively
maintained, Acute and Critical Care Surgery (ACCS) da-
tabase spanning 2008–2015 and including more than 7,000
patients was queried for patients with an International Clas-
sification of Diseases (ICD)-9 diagnosis of PPU disease of the
stomach or duodenum with or without obstruction (ICD-9
codes 531.1x, 531.2x, 531.5x, 531.6x, 532.1x,532.2x, 532.5x,
and 532.6x).
All patients with an ICD-9 diagnosis of a PPU were
evaluated by an investigator to confirm the accuracy of
the coding information. Sites of perforation, pre-operative
medications, duration of symptoms, microbiologic data,
social history, demographics, and clinical outcomes were
abstracted. The Charlson/Deyo Comorbidity Index was ap-
plied as previously described [16,17]. The microbiologic data
abstracted consisted of intra-operative peritoneal fluid cul-
tures and results from post-operative blood, urine, sputum,
and interventional radiology (IR)-guided drain cultures as
appropriate.
Intra-operative fungal cultures are collected on flocked
nylon swabs and transported in Liquid Amies medium [18].
The swab and media are then vortexed and plated on Blood
Heart Infusion, Inhibitory Mold, and Sabourand dextrose with
chloramphenicol agars. Samples are incubated for 28 days at
30C and checked daily. Once grown, molds are identified
with light microscopy, and yeasts are identified via matrix-
assisted laser desorption/ionization time of flight mass spec-
trometry (MALDI-TOF MS) (Melanie Yarbrough, PhD, oral
communication, February 25, 2017).
Demographics and outcomes of patients who received pre-
operative anti-fungal therapy were compared with those who
did not using univariable analysis. We then defined an estab-
lished intra-abdominal infection as the presence of symptoms
for more than 24 hours. Univariable analysis of this subgroup
was performed in similar fashion. Finally, the subgroup of
patients with intra-operative peritoneal fluid cultures yielding
fungal growth and patients without such growth were evalu-
ated in similar fashion. Frequencies were compared by the
Fisher exact or w2 test as appropriate and continuous variables
by the Student t-test.
Results
There were 118 patients with PPU treated at our institution
during the study period; 107 patients had operative therapy,
and 27 (25.2%) received empiric pre-operative anti-fungal
therapy. The average age was 55.9 (standard deviation [SD]
17.6) years; 57 (53.3%) of the patients were female, and the
average Body Mass Index (BMI) was 26.7 (SD 7.2). Patients
who received pre-operative anti-fungal drugs were more
likely to be taking H2-blockers than those who did not (11.1%
vs 0; p = 0.02). There were no other significant differences in
the demographics of patients who received anti-fungal ther-
apy and those who did not. Complete demographics are shown
in Table 1.
There were 33 patients (30.8%) who had intra-operative
peritoneal fluid cultures; 17 (51.5%) grew fungus. Although
there were no statistically significant differences, patients
with fungi recovered were more likely to have a gastric
Table 2. Fungal Species Recovered
from Intra-Operative Peritoneal Fluid Cultures
Species No. (%)
Candida albicans 9 (53)
Yeast (unspeciated) 6 (35)
C. glabrara 1 ( 6)
C. krusei 1 ( 6)
C. tropicalis 1 ( 6)
Percentages sum to greater than 100% because multiple species
were present in some cultures.
Table 3. Outcomes of Patients with Perforated Peptic Ulcer According to Receipt
of Empiric Pre-Operative Anti-Fungal Therapy
Total (n = 107) No anti-fungal (n = 80) Anti-fungal (n = 27)
In-hospital death (%) 5 ( 4.7) 4 ( 5.0) 1 ( 3.7)
Mean LOS (SD) 14.2 (13.2) 13.9 (12.5) 15.2 (15.4)
Mean ICU LOS (SD) 6.7 (11.8) 6.7 (11.1) 6.7 (13.9)
Mean ventilator days (SD) 2.4 ( 6.3) 2.8 ( 7.0) 1.4 ( 3.5)
30-day re-admission (%) 19 (17.8) 15 (18.8) 4 (14.8)
Intra-abdominal abscess (%) 7 ( 6.5) 5 ( 6.3) 2 ( 7.4)
Post-op intra-abdominal fungal abscess (%) 3 ( 2.8) 2 ( 2.5) 1 ( 3.7)
Fungemia (%) 1 ( 0.9) 1 ( 1.3) 0
None of the differences is statistically significant.
ICU = intensive care unit; LOS = length of stay; SD = standard deviation.















































perforation than patients without fungal growth (58.8% vs.
25.0%; p = 0.07). All fungal species recovered were yeast;
complete speciation is shown in Table 2.
Of the 27 patients who received pre-operative anti-fungal
therapy, 23 (85%) received fluconazole; three (11%) re-
ceived micafungin, and one (4%) received anidulafungin.
In order to determine the effect of anti-fungal therapy, we
compared in-hospital death, length of stay (LOS), intensive
care unit (ICU) LOS, ventilator days, 30-day re-admission
rate, formation of intra-abdominal abscesses, fungemia, and
number of operations in patients who received empiric anti-
fungal therapy and patients who did not. The outcomes are
shown in Table 3.
We then compared outcomes of patients who had fungal
growth in their intra-operative peritoneal fluid cultures and
those who did not. There were no significant differences in
demographics, nor were there differences in any measured
outcomes. Outcomes according to the presence of fungal
species are shown in Table 4.
Next, we attempted to determine whether anti-fungal
agents were helpful in patients with established intra-
abdominal infections, defined by the presence of symptoms
for >24 hours. Of the 107 patients with operatively managed
PPU, 60 (56%) presented >24 hours after the onset of
symptoms. There were no significant differences in the rate
of fungal isolation between patients who had <24 hours of
symptoms and those with >24 hours of symptoms (86% vs.
67%; p = 0.39). Among patients with >24 hours of symptoms,
there were no differences in outcomes between patients who
received pre-operative anti-fungal therapy and those who did
not (Table 5).
Finally, we compared the outcomes in patients with fungal
isolates who received pre-operative anti-fungal therapy
with those who did not. Of the 17 patients with fungal iso-
lates present in the abdomen at surgery, 4 (24%) received
pre-operative anti-fungal therapy. There were no significant
differences in demographics between the groups or in the post-
operative outcomes. Outcomes of patients with confirmed fun-
gal isolates are available in Supplemental Table 1. There was no
difference in the incidence of post-operative anti-fungal use
between those who received anti-fungal drugs pre-operatively
and those who did not (75% vs. 77%; p = 1.0).
Discussion
The rates of Candida recovered in the peritoneal fluid of
patients with PPU have ranged from 27% to 57%. In 1986,
Peoples found that Candida was associated with advanced
age and shock and concluded that Candida was not patho-
genic and therefore did not warrant systemic anti-fungal
therapy [7]. More recently, Shan et al. analyzed 145 patients
with PPU and purulent ascites; 63 (43%) had fungal species
isolated. Patients with fungal infections had longer LOS, a
higher in-hospital mortality rate, and more surgical site in-
fections, although they also were likely to present later and
to be sicker on admission [9]. In a retrospective analysis
of 133 patients with Candida caused by PPU at the same
institution, there were no differences in outcomes between
patients started on post-operative anti-fungal drugs and those
who were not [13]. Thus, those authors believed that anti-
fungal therapy was indicated only for patients who were
immunocompromised or critically ill [13].
Table 4. Outcomes of Patients with Perforated Peptic Ulcer by Presence
of Fungal Species in Intra-Operative Peritoneal Fluid
a
Total (n = 33) No fungus (n = 16) Fungus (n = 17)
In-hospital death (%) 1 ( 3.0) 1 ( 6.3) 0
Mean LOS (SD) 15.3 (13.4) 13.1 (10.0) 17.4 (16.0)
Mean ICU LOS (SD) 5.9 ( 8.7) 4.9 ( 7.0) 6.9 (10.2)
Mean ventilator days (SD) 2.6 ( 4.5) 2.4 ( 4.5) 2.7 ( 4.6)
30-day re-admission (%) 8 (24.2) 2 (12.5) 6 (35.3)
Intra-abdominal abscess (%) 2 ( 6.1) 1 ( 6.3) 1 ( 5.9)
Post-op. intra-abdominal fungal abscess 2 ( 6.1) 1 ( 6.3) 1 ( 5.9)
aThere were no cases of fungemia, and none of the differences is statistically significant.
ICU = intensive care unit; LOS = length of stay; SD = standard deviation.
Table 5. Outcomes of Patients Having >24 h of Symptoms by Receipt of Pre-Operative Anti- Fungal Therapy
Total No anti-fungal Anti-fungal
N (%) 60 (100) 45 (75.0) 15 (25.0)
In-hospital death (%) 3 ( 5.0) 2 ( 4.4) 1 ( 6.7)
Mean LOS (SD) 12.4 ( 11.5) 12.2 (11.4) 13.0 (12.3)
Mean ICU LOS (SD) 4.4 ( 8.1) 5.3 ( 8.3) 3.3 ( 7.2)
Mean ventilator days (SD) 1.4 ( 3.1) 1.8 ( 3.3) 0.47 ( 1.8)
30-day re-admission (%) 10 ( 16.7) 8 (17.8) 2 (13.3)
Intra-abdominal abscess (%) 5 ( 8.3) 4 ( 8.9) 1 ( 6.7)
Post-op. intra-abdominal fungal abscess (%) 2 ( 3.3) 2 ( 4.4) 0
Fungemia (%) 1 ( 1.7) 1 ( 2.2) 0
None of the differences is statistically significant.















































Two prospective studies have evaluated intra-operative
or pre-operative anti-fungal therapy in patients with gastric
perforation [11,12]. The Norwegian Yeast Study Group
performed peritoneal fluid cultures on 109 patients with
gastrointestinal perforations or anastomotic leaks and ran-
domized them to intra-operative fluconazole or placebo
[12]. Those investigators found no statistically significant
difference in the mortality rate; however only 22 patients
had gastroduodenal perforations, and no subgroup analysis
was performed [12]. Eggimann et al. randomized 49 pa-
tients with recurrent gastrointestinal perforations or anas-
tomotic leaks to post-operative daily fluconazole or placebo
and found that prophylaxis prevented intra-abdominal
Candida infections but did not improve the mortality rate
[11]. Only five patients were classified as having upper
gastrointestinal tract perforations [11]. Both the Surgical
Infection Society and the Infectious Diseases Society of
America recommend empiric anti-fungal therapy for pa-
tients with intra-abdominal infections after gastrointestinal
leaks, defined as patients who have an upper gastrointestinal
leak prior for ‡24 hours prior to source control [19,20].
Consistent with previous findings, we recovered fungal
species from 52% of the peritoneal fluid cultures. There were
no differences in outcomes or demographics in the group with
positive fungal cultures and those with negative cultures. At
our institution, the choice of whether to treat with empiric
pre-operative anti-fungal therapy is made by the attending
physician. There were no differences in demographics or
outcomes between the patients who received pre-operative
anti-fungal drugs and those who did not, either in the entire
cohort or in patients who underwent operative management
>24 hours except that patients on H2-blocker therapy were
more likely to receive pre-operative anti-fungal drugs. In
contrast to prior studies, we found no significant difference in
patients with fungal isolates recovered at the time of surgery.
These data suggest that pre-operative anti-fungal therapy is
unnecessary in patients with PPU.
Our study has important limitations. Most notably, this was
a single-center study, which may limit its reproducibility. At
our institution, the choice of whether to use pre-operative
anti-fungal drugs is attending-physician dependent, as is the
choice to obtain intra-operative peritoneal fluid cultures. It
is unclear what drove the decision to give some patients pre-
operative anti-fungal drugs and not others; however, we
believe that the difference in pre-operative anti-fungal us-
age in patients receiving H2-blocker therapy is the result
of attending physician preference. Because this was a
non-randomized study, it is possible that the patients given
anti-fungal drugs were more ill than those who were not.
We attempted to account for this by comparing the two
groups’ Charlson/Deyo Comorbidity indices and Ameri-
can Society of Anesthesiologists scores, as previous work
has suggested that these scores are valid for predicting
outcomes in PPU [21]. Although there are several PPU-
specific scores available, we were unable to calculate them
because of limitations in the data available [21]. Finally,
we have only a small number of patients with confirmed
fungal infections, increasing the probability of Type II
error.
In summary, in this retrospective, single-center study of
107 patients with operatively confirmed PPUs, there was no
difference in outcomes between patients who received em-
piric pre-operative anti-fungal therapy and those who did not.
More than half of the patients with intra-operative peritoneal
cultures were infected with yeast species. There were no
significant differences in outcomes between patients with and
without fungal contamination or in those who received anti-
fungal therapy with confirmed fungal contamination and
those who did not. On the basis of these data, patients with
PPUs do not require empiric anti-fungal therapy, although
further study is needed to confirm this view.
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